Asociación Española
de Gastroenterología
Enfermedad Inflamatoria Intestinal

Pilar Nos Mateu
Coordinador

El Grupo de Trabajo de Enfermedad Inflamatoria Intestinal de la AEG está formado mayoritariamente por miembros del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Es objetivo primordial del grupo el estudio y la investigación de la Enfermedad Inflamatoria Intestinal (EII): enfermedad de Crohn y colitis ulcerosa y la homologación de criterios clínico-terapéuticos en el diagnóstico y tratamiento de la misma.


Does Smoking Influence Crohns Disease in the Biologic Era. The Tabacrohn Study
53

Autores:
Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Acosta MB, Bastida G, García S, Gento E, Ginard D, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; for the TABACROHN Study Group of GETECCU, Spanish Working Group in Crohnʼs Disease and Ulcerative Colitis. Referencia: Inflamm Bowel Dis. 2013 Jan;19(1):23-29.

BACKGROUND:
While most studies have found a negative effect of smoking on Crohn's disease (CD) phenotype, more recent data have failed to reproduce this association, which might be due to a current wider use of thiopurines and biologic therapy. The TABACROHN study aimed at defining the impact of smoking on CD in the largest published series.

METHODS:
This multicenter cross-sectional study included 1170 CD patients. Patients were classified as nonsmokers, current smokers, or former smokers according to their present smoking status. Clinical data regarding disease characteristics, treatment, and complications were collected.

RESULTS:
Smokers were more frequently under maintenance treatment when compared to nonsmokers. In addition, current smokers presented higher use of biologic drugs compared to nonsmokers. Tobacco exposure and a higher tobacco load were independent predictors of need for maintenance treatment and stenosing phenotype, respectively.

CONCLUSIONS:
In the era of early and widespread use of immunosuppressants and biologics, tobacco exposure is an independent predictor of need for maintenance treatment, specifically biologic therapy. The wider use of biologics and immunosuppressants could account for the existence of no major differences in disease behavior and complications between nonsmokers and current smokers.